Adding one year of IMFINZI treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and ...

The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for the treatment of adult ...

Imfinzi is the first perioperative immunotherapy approved for resectable gastric/GEJ cancers, offering a new treatment ...

AstraZeneca’s Imfinzi (durvalumab) has been granted priority review by the US Food and Drug Administration (FDA) to treat early ...

AstraZeneca’s Imfinzi (durvalumab), in combination with standard of care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin and docetaxel), has been approved by the US FDA to treat adult ...

AstraZeneca’s Imfinzi approved in US as first and only perioperative immunotherapy for patients with early gastric and GEJ cancers: Cambridge, UK Thursday, November 27, 2025, 09 ...

Adding one year of IMFINZI treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and ...

The US Food and Drug Administration approved AstraZeneca’s Imfinzi (durvalumab) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, ...

LONDON (dpa-AFX) - AstraZeneca's (AZN) Phase III MATTERHORN trial showed that perioperative treatment with IMFINZI (durvalumab ...

FDA approves AstraZeneca's Imfinzi plus FLOT for early gastric and GEJ cancers after Phase 3 data show strong event-free and overall survival benefits.

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with ...

AstraZeneca AZN presented updated long-term data from the follow-up of phase III PACIFIC study, evaluating its PD-L1 inhibitor ...